The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Primary analysis of the ELM-2: odronextamab in heavily pretreated R/R FL
Michał Taszner, MD, Medical University of Gdańsk, Gdańsk, Poland, presents the primary analysis of the Phase II ELM-2 study (NCT03888105) investigating odronextamab in heavily pretreated patients with relapsed/refractory (R/R) follicular lymphoma (FL). This bispecific antibody had a generally manageable safety profile and elicited deep and durable responses in a difficult-to-treat patient population, with responses consistent between pre-specified risk groups. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Takeda, Roche, BeiGene, Novartis, Janssen; Travel grants: Beigene.
